| Summary of Selected Financial Information with Respect to Single Operating Segment |
The following table presents selected financial information with respect to the Company’s single operating segment for the eight-month period ended December 31, 2025 and twelve months ended April 30, 2025 and 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
Eight Months Ended
December 31, |
|
Twelve Months Ended
April 30, |
|
|
2025 |
|
2025 |
|
2024 |
Product revenue, net |
|
$ |
49,078 |
|
$ |
— |
|
$ |
— |
Segment expenses and other segment items |
|
|
|
|
|
|
|
|
|
Cost of revenue |
|
|
3,081 |
|
|
— |
|
|
— |
Clinical development |
|
|
14,723 |
|
|
43,166 |
|
|
46,520 |
Research |
|
|
12,851 |
|
|
19,713 |
|
|
36,074 |
Regulatory & QA |
|
|
5,239 |
|
|
8,830 |
|
|
3,573 |
Commercial |
|
|
89,441 |
|
|
62,859 |
|
|
18,481 |
Other SG&A |
|
|
35,780 |
|
|
53,427 |
|
|
35,797 |
Other income |
|
|
(1,480) |
|
|
(7,943) |
|
|
(13,801) |
Income tax (benefit) expense |
|
|
(1,033) |
|
|
3,392 |
|
|
— |
Segment net loss |
|
|
(109,524) |
|
|
(183,444) |
|
|
(126,644) |
|
|
|
|
|
|
|
|
|
|
Reconciliation of segment profit or loss: |
|
|
|
|
|
|
|
|
|
Adjustments and reconciling items |
|
|
— |
|
|
— |
|
|
— |
Consolidated net loss |
|
$ |
(109,524) |
|
$ |
(183,444) |
|
$ |
(126,644) |
|